ArticleScientific reports2025
Endocan expression and correlation with other endothelial determinants in developing a score for early identification of diabetic peripheral neuropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased C-reactive protein is associated with corneal nerve loss and painful neuropathic symptoms in Type 2 diabetes mellitus.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic peripheral neuropathy is a common complication of diabetes mellitus that has dire outcomes, affecting the economic profile of a country. Despite the multifactorial background of the pathogenesis of this disease, the mechanism underlying peripheral neuropathy is still unclear. Endothelial damage is a new determinant of pathogenesis, with endocan as a potential biomarker for endothelial dysfunction in diabetic peripheral neuropathy patients. In this cross-sectional study, with 49 patients with diabetes with peripheral neuropathy and 48 patients with diabetes without neuropathy, endothelial biomarkers such as endocan, hs-CRP, vitamin D, and lipid profiles were measured and analyzed in both groups. The standardized scores for dyslipidemia, inflammation, vitamin D and endocan were calculated. All of these biomarkers were significantly altered in peripheral neuropathy patients. A strong correlation between endocan levels and lipid profiles and between hs-CRP and vitamin D levels was detected. The inflammatory score and a combined score including all the above biomarkers might help in the early stratification of diabetic patients who are at greater risk of developing peripheral neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.